Stock CERE CEREVEL THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
41.9 USD -0.24% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.72% -1.18%
Apr. 18 Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Apr. 18 Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study MT

Business Summary

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Number of employees: 334

Managers

Managers TitleAgeSince
Ronald Renaud CEO
 Chief Executive Officer 55 23-06-11
Susan Altschuller DFI
 Director of Finance/CFO 43 23-05-14
N. Coles CHM
 Chairman 63 18-11-30
Raymond Sanchez CTO
 Chief Tech/Sci/R&D Officer 63 18-12-31
John Renger CTO
 Chief Tech/Sci/R&D Officer 55 19-04-30
Kathleen Tregoning
53 -
Matthew Calistri IRC
 Investor Relations Contact - -
Scott Akamine LAW
 General Counsel 40 21-05-23
Mark Bodenrader AUD
 Comptroller/Controller/Auditor 51 19-08-31
Paul Burgess PRN
 Corporate Officer/Principal 50 23-06-19

Members of the board

Members of the board TitleAgeSince
Gabrielle Greene-Sulzberger BRD
 Director/Board Member 63 19-05-31
Douglas Giordano BRD
 Director/Board Member 61 18-08-31
Ruth McKernan BRD
 Director/Board Member 66 20-12-03
Deval Patrick BRD
 Director/Board Member 67 21-01-19
Marijn Dekkers BRD
 Director/Board Member 65 18-08-31
Norbert Riedel BRD
 Director/Board Member 66 18-11-30
N. Coles CHM
 Chairman 63 18-11-30
Ronald Renaud CEO
 Chief Executive Officer 55 23-06-11
Christopher Gordon BRD
 Director/Board Member 51 18-08-31
Adam Koppel BRD
 Director/Board Member 54 18-08-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 181,576,482 76,702,134 ( 42.24 %) 0 42.24 %

Shareholders

NameEquities%Valuation
Bain Capital Private Equity LP
36.17 %
65,679,781 36.17 % 2 776 M $
PFIZER, INC.
15.06 %
27,349,211 15.06 % 1 156 M $
Perceptive Advisors LLC
6.039 %
10,965,193 6.039 % 463 M $
Perceptive Advisors LLC
5.945 %
10,794,876 5.945 % 456 M $
Fidelity Management & Research Co. LLC
5.338 %
9,691,851 5.338 % 410 M $
Avoro Capital Advisor LLC
4.161 %
7,555,555 4.161 % 319 M $
Vanguard Fiduciary Trust Co.
4.062 %
7,374,970 4.062 % 312 M $
BlackRock Advisors LLC
3.151 %
5,721,190 3.151 % 242 M $
STATE STREET CORPORATION
1.571 %
2,851,819 1.571 % 121 M $
Fidelity Investments Canada ULC
1.523 %
2,766,000 1.523 % 117 M $

Company contact information

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street Suite 200

02141, Cambridge

+844 304 2048

http://www.cerevel.com
address Cerevel Therapeutics Holdings, Inc.(CERE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
41.9 USD
Average target price
44.78 USD
Spread / Average Target
+6.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CEREVEL THERAPEUTICS HOLDINGS, INC. Stock Cerevel Therapeutics Holdings, Inc.
-1.18% 7.61B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.80% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-9.12% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CERE Stock
  4. Company Cerevel Therapeutics Holdings, Inc.